AU2020347539B2 - Compositions for the treatment of solid tumors - Google Patents

Compositions for the treatment of solid tumors

Info

Publication number
AU2020347539B2
AU2020347539B2 AU2020347539A AU2020347539A AU2020347539B2 AU 2020347539 B2 AU2020347539 B2 AU 2020347539B2 AU 2020347539 A AU2020347539 A AU 2020347539A AU 2020347539 A AU2020347539 A AU 2020347539A AU 2020347539 B2 AU2020347539 B2 AU 2020347539B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
compound
weight
acid
composition comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020347539A
Other languages
English (en)
Other versions
AU2020347539A1 (en
Inventor
Eran Blaugrund
Alon BLOOMENFELD
Racheli GUETA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Raziel Therapeutics Ltd
Original Assignee
Raziel Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raziel Therapeutics Ltd filed Critical Raziel Therapeutics Ltd
Publication of AU2020347539A1 publication Critical patent/AU2020347539A1/en
Application granted granted Critical
Publication of AU2020347539B2 publication Critical patent/AU2020347539B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020347539A 2019-09-15 2020-09-14 Compositions for the treatment of solid tumors Active AU2020347539B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900557P 2019-09-15 2019-09-15
US62/900,557 2019-09-15
PCT/IB2020/000745 WO2021048626A1 (en) 2019-09-15 2020-09-14 Compositions for the treatment of solid tumors

Publications (2)

Publication Number Publication Date
AU2020347539A1 AU2020347539A1 (en) 2022-03-31
AU2020347539B2 true AU2020347539B2 (en) 2026-06-04

Family

ID=74866186

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020347539A Active AU2020347539B2 (en) 2019-09-15 2020-09-14 Compositions for the treatment of solid tumors

Country Status (7)

Country Link
US (1) US20220323411A1 (cg-RX-API-DMAC10.html)
EP (1) EP4031130A4 (cg-RX-API-DMAC10.html)
JP (1) JP7822308B2 (cg-RX-API-DMAC10.html)
CN (1) CN115066241A (cg-RX-API-DMAC10.html)
AU (1) AU2020347539B2 (cg-RX-API-DMAC10.html)
IL (1) IL291351B1 (cg-RX-API-DMAC10.html)
WO (1) WO2021048626A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016203468A1 (en) 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
WO2022234337A2 (en) * 2021-05-06 2022-11-10 Raziel Therapeutics Ltd. Crystalline carbazole derivative
WO2024100533A1 (en) * 2022-11-07 2024-05-16 Raziel Therapeutics Ltd. Crystalline carbazole derivative and methods of making thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042445A1 (en) * 2008-10-06 2010-04-15 Cleveland Biolabs, Inc. Carbazole compounds and therapeutic uses of the compounds
WO2013072915A1 (en) * 2011-11-15 2013-05-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Tricyclic compounds, compositions comprising them and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0311406D0 (en) * 2003-05-17 2003-06-25 Queen Mary & Westfield College Substituted phosphonate fluorescent sensors,and use thereof
WO2016203468A1 (en) * 2015-06-15 2016-12-22 Raziel Therapeutics Ltd. Carbazole derivatives for the treatment of fibrotic diseases and related symptoms, and conditions thereof
AU2021213469B2 (en) * 2020-01-28 2026-06-04 Raziel Therapeutics Ltd. Compositions for the treatment of angiolipoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042445A1 (en) * 2008-10-06 2010-04-15 Cleveland Biolabs, Inc. Carbazole compounds and therapeutic uses of the compounds
WO2013072915A1 (en) * 2011-11-15 2013-05-23 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Tricyclic compounds, compositions comprising them and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CARMELA SATURNINO ET AL: "Inhibition of Human Topoisomerase II by N,N,N-Trimethylethanammonium Iodide Alkylcarbazole Derivatives", CHEMMEDCHEM COMMUNICATIONS, vol. 13, no. 24, (2018), pages 2635 - 2643, DOI: 10.1002/CMDC.201800546 *

Also Published As

Publication number Publication date
IL291351B1 (en) 2026-07-01
JP2023503769A (ja) 2023-02-01
CN115066241A (zh) 2022-09-16
AU2020347539A1 (en) 2022-03-31
US20220323411A1 (en) 2022-10-13
EP4031130A4 (en) 2023-10-11
JP7822308B2 (ja) 2026-03-02
EP4031130A1 (en) 2022-07-27
IL291351A (en) 2022-05-01
WO2021048626A1 (en) 2021-03-18